Health economic guidelines--similarities, differences and some implications.
about
Do economic evaluation studies inform effective healthcare resource allocation in Iran? A critical review of the literatureCost-effectiveness analysis of a communication-focused therapy for pre-school children with autism: results from a randomised controlled trial.Where is the future in public health?Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicineFinancial evaluations of antibiotic stewardship programs-a systematic reviewCost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modelingModelling lifetime cost consequences of ReSTOR in cataract surgery in four European countries.The greatest happiness of the greatest number? Policy actors' perspectives on the limits of economic evaluation as a tool for informing health care coverage decisions in ThailandCosts and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database.Spectacle independence and subjective satisfaction of ReSTOR multifocal intraocular lens after cataract or presbyopia surgery in two European countriesTreatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research databaseStatistical methods for cost-effectiveness analyses that use data from cluster randomized trials: a systematic review and checklist for critical appraisal.Measuring the value of older people's production: a diary study.The DARE study of relapse prevention in depression: design for a phase 1/2 translational randomised controlled trial involving mindfulness-based cognitive therapy and supported self monitoring.Current Status and Future Prospects of Clinical Psychology: Toward a Scientifically Principled Approach to Mental and Behavioral Health Care.Cost per QALY (quality-adjusted life year) and lifetime cost of prolonged mechanical ventilation in Taiwan.Health-care costs of losartan and candesartan in the primary treatment of hypertension.Measuring preferences for cost-utility analysis: how choice of method may influence decision-makingPharmacoeconomic studies in Nepal: the need of the hour.Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P).Pharmaco-economics of blood transfusion safety: review of the available evidence.Biosimilar medicines and cost-effectiveness.Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes.The cost-effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet.Pharmacoeconomics: friend or foe?Cost-effectiveness of antenatal HIV-testing: reviewing its pharmaceutical and methodological aspects.Economic evaluations in Italy: a review of the literature.Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdleState of health economic evaluation research in Saudi Arabia: a review.Convergent validity of the interRAI-HC for societal costs estimates in comparison with the RUD Lite instrument in community dwelling older adultsProtocol for a systematic review of preference-based instruments for measuring care-related outcomes and their suitability for the palliative care setting.Quality-adjusted life years: how useful in medico economic studies.Assessing generalisability in model-based economic evaluation studies: a structured review in osteoporosis.Quality assessment of published health economic analyses from South America.Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems).Could CT screening for lung cancer ever be cost effective in the United Kingdom?The economics of primary prevention of cardiovascular disease - a systematic review of economic evaluationsEconomic studies part 2: evaluating the qualityThe use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: Methodological recommendations.
P2860
Q26852348-9CD152DE-2F7F-4C3C-91F9-6394308BE608Q27311227-FA09C6CA-0F2D-4695-A499-EA201D76B67CQ28748486-3F859E38-A42A-4278-B5C4-4A9899FF9C76Q28756810-AA602B22-9D3F-4B07-902B-831E74855492Q30640528-83775DEB-D234-40AD-9D17-0252C98503E6Q31119280-71773066-24B2-4354-AAF8-4B869D01CDD9Q33351755-3BCE6CE6-3850-4193-A97A-CE3A18D6B560Q33372003-7F3023E6-ECD0-4D29-A922-460BC329FA9CQ33492365-DB1719BD-2BCD-4699-9F1D-7942E519E903Q33715285-E49C02BE-A2AB-4B15-AC67-E89FFECA5D96Q33863644-905F423D-8F61-4D1A-9EEF-E07F5453B7B6Q33910824-E8436C5D-2E0C-4F6B-97D8-DB1D38947AA6Q34122221-E9EC97F5-5253-41FF-A762-DA97FAE3FF43Q34133355-D63FC469-8AE8-4D57-8799-404D791B8B03Q34145173-193A18B2-903B-45B4-84FC-00E5E86271A1Q34412177-B6F25C77-AFCE-4C9B-B5E0-AD6D12C17976Q34501177-EB5F3956-1D3E-41ED-9CE8-1EEC0A740ABEQ34614168-6CF5177B-0EE0-4C90-B90B-039574BA1BE3Q34650925-9E9CF4AA-A1FA-479C-AF60-9C8F4B1DA4E4Q34773861-03E82F5C-E6D0-43E1-B773-3F3EE7F2D33CQ34803014-EA43EBB0-9AAC-4CB7-A957-AD457FD8FDB3Q35205419-C91A88F5-C2F1-43BD-A470-DBB8BF8AD6D1Q35207593-29A7EDB9-F9C6-42D8-A9B4-CED8559FB882Q35635182-6B36DFEF-59D2-4198-9CB6-D7BBCCCD5392Q35638247-51AF2989-3483-478E-9B43-422B7B335158Q35688148-EE08F913-83B9-48CA-8254-1610EF5E59B7Q35750546-7949C2EF-140A-4568-BCB9-E73F2A1E13DAQ35878722-AF6F2BF9-FDE7-4B2D-A40C-CFC9CB63AFDCQ35925125-F872C688-FC87-48AE-A768-08B09B9021AAQ36106033-DEC3093A-8682-48D3-B04A-21F2E1A77BB6Q36113322-585EC6F3-0249-4D44-840A-FC28BDEE63EBQ36130599-1F5AFF41-CFF7-457E-B4C6-17C39F54354BQ36324871-6450D229-6ADD-4913-B2EF-80897CDC7635Q36439111-5270F44C-6232-44BC-826B-75B45B28387EQ36466893-26473E0F-9E23-4310-AC45-397FAD64A4C4Q36468092-190F3EC7-E0F7-4094-A79D-8B4E5B37001FQ36537744-86B632A0-FCA8-4AE2-8DEA-799F64D69905Q36821473-3A0A4462-A80D-457E-8A91-C83DB3A99003Q36975666-3283B9C8-ECAA-49D2-9B4D-CDE320F5011FQ37099269-C557BC1A-5297-4F78-B9E5-AC86B89E9A0D
P2860
Health economic guidelines--similarities, differences and some implications.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Health economic guidelines--similarities, differences and some implications.
@ast
Health economic guidelines--similarities, differences and some implications.
@en
Health economic guidelines--similarities, differences and some implications.
@nl
type
label
Health economic guidelines--similarities, differences and some implications.
@ast
Health economic guidelines--similarities, differences and some implications.
@en
Health economic guidelines--similarities, differences and some implications.
@nl
prefLabel
Health economic guidelines--similarities, differences and some implications.
@ast
Health economic guidelines--similarities, differences and some implications.
@en
Health economic guidelines--similarities, differences and some implications.
@nl
P2093
P1433
P1476
Health economic guidelines--similarities, differences and some implications.
@en
P2093
Andersson F
Berggren F
Hjelmgren J
P304
P356
10.1046/J.1524-4733.2001.43040.X
P577
2001-05-01T00:00:00Z